Joint Formula Curcumin with Meriva Curcumin
Joint Formula Curcumin
with Meriva® Curcumin
$39.95Relieves joint inflammation and associated symptoms Joint Formula CurcuminTM with Meriva® curcumin provides antioxidants for the maintenance of good health. Joint Formula Curcumin blends premium, well-researched Meriva® Curcumin with half a dose of SierraSil mineral complex. Curcumin is the natural active ingredient in the spice turmeric, and is clinically proven to have a higher analgesic effect than acetaminophen.* It’s guaranteed effective, all natural and significantly easier to digest than other pain relievers. Vegetarian friendly and Non-GMO. *Journal of Pain Research, 2013 90 Capsules (30 Day Supply)
Product DescriptionJoint Formula Curcumin™ contains both SierraSil®, a pure, all natural mineral complex, and Meriva® curcumin, a natural pain reliever clinically proven to have a higher analgesic effect than acetaminophen at a 2 gram dose.1 SierraSil has health promoting properties and supports gentle detoxification due to its rich clay-like mineral structure. Its charged and porous structure attracts and binds positively charged toxins, harmful bacteria and viruses as well as heavy metals, pesticides and other common chemical toxins, facilitating their safe removal from the body.2 Meriva® is a good source of antioxidants, which provide numerous health benefits including joint health support and assistance with maintaining the body’s normal inflammatory response. Joint Formula Curcumin is only available in Canada. Each capsule contains: SierraSil® 300 mg (naturally occurring hydrothermal mineral complex) Meriva 335 mg (providing 201 mg curcuminoids-phosphatidylcholine complex (33% curcuminoids), source material Curcuma Longa-Rhizome) Non-medicinal ingredients: Magnesium stearate, microcrystalline cellulose, silicon dioxide, hypromellose Footnotes: 1) Di Pierro, Francesco, Rapacoli et al. 2013. Comparative evaluation of the pain-relieving properties of a lecithinized formulation of curcumin (Meriva®), nimesulide, and acetaminophen. Journal of Pain Research. Vol 3. No 6: 201-05. 2) Johns, T; Duquette, M. Detoxification and mineral supplementation as functions of geophagy. American Journal of Clinical Nutrition. 1991, Vol/Issue: 53:2, 448-56.
Serving GuidelinesTake 1 capsule 3 times a day right after a meal. Drink a minimum of 6 glasses of water per day. Call Customer Service if you have any questions, including the best time to take SierraSil Joint Formula Active™. Caution: Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Consult a health care practitioner prior to use if you are taking antiplatelet medication or blood thinners, or if you have gallstones or a bile duct obstruction, stomach ulcers or excess stomach acid. Consult a health care practitioner if symptoms persist or worsen. If you have any additional questions, please call Customer Service at 1-877-743-7720.
CertificationHealth Canada Natural Product Number Health Canada has awarded SierraSil Health the Natural Product Number (NPN) for Joint Formula Curcumin. The approved "recommended use or purpose" for Joint Formula Curcumin (NPN 80054432) is "Helps relieve joint inflammation and associated symptoms such as joint pain when used in conjunction with conventional treatment. Provides antioxidants for the maintenance of good health."
Clinical SupportFor information on the clinical research behind SierraSil’s unique mineral complex, please visit the Joint Formula 14™ page. Meriva® has also been studied extensively, the following is a brief compilation of the research associated with joint health and physical function: Comparative Study The pain relieving properties of Meriva® were evaluated against that of Nimesulide and Acetaminophen. Results: The analgesic effect of Meriva® was higher than that associated with acetaminophen while its gastric tolerability was significantly better at a 2 gram dose than that of Nimesulide. Di Pierro, Francesco, Rapacoli et al. 2013. Comparative evaluation of the pain-relieving properties of a lecithinized formulation of curcumin (Meriva®), nimesulide, and acetaminophen. Journal of Pain Research. Vol 3. No 6: 201-05. Safety and Efficacy Study The long-term efficacy and safety of Meriva® were investigated in an 8-month study involving 100 patients suffering from Osteoarthritis. Results: Meriva® was deemed “an effective and safe agent for the complementary management of osteoarthritis, leading to better disease control and overall improvement in quality of life.” Belcaro, Gianni, Cesarone et al. 2010. Efficacy and Safety of Meriva®, a Curcumin-phosphatidylcholine Complex, during Extended Administration in Osteoarthritis Patients. Alternative Medicine Review. Vol 15. No 4: 337-43. Systemic Availability Study The oral bioavailability of Meriva® brand curcumin was studied alongside that of unformulated curcumin. Results: Plasma level values were fivefold higher for Meriva® than the equivalent values seen with unformulated curcumin. Marczylo, Timothy, Verschoyle et al. 2007. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60: 171-77. Meriva® and the complementary management of bone and joint health Meriva® was evaluated for its efficacy in 50 individuals affected by bone health challenge (X-ray diagnosis confirmation). The symptoms were evaluated by the WOMAC score; mobility was studied by walking performance on the treadmill and the overall inflammatory response function was assessed by measurements of C-reactive protein plasma concentration. Results: The treadmill performance (10% inclination, 3 Km/h speed) showed an improvement of 201% of the initial walked distance at two months, and a further improvement (+44%) at three months from the beginning of the study. These positive results were complemented by secondary end-points, namely the decrease in supplemental therapy use (63% in the Meriva® group vs 12% in the treatment group) and the decrease in gastrointestinal complications (38% in Meriva® vs 15% in controls (p<0.05). Overall, the management costs in the Meriva® group decreased by 49% compared to a non significant 3% decrease for the control group. 0> Belcaro G., et al., Panminerva Medica, 2010, 52(2 Suppl 1): p. 55-62. Meriva® for the maintenance of bone health Meriva® was further confirmed in a larger and longer (8 months) investigation, that enrolled 100 participants and was, otherwise, methodologically similar to the previous one, including the dosage (1 g/day of Meriva®, corresponding to 200 mg curcumin/day in two separate administrations). Results: The results showed that the Meriva® group enjoyed a statistically significant reduction in all primary clinical endpoints, the Western Ontario and McMaster Universities (WOMAC) score (decreased from 80.6 to 33.2), the Karnofsky Performance Scale (improved from 73.3 to 92.2), and the treadmill walking performance test. These results were complemented by the evaluation of a series of inflammatory response function markers wider than the one considered in the first study (interleukin
(15 Day Supply)